InvoX Pharma’s F-star announces licence agreement with Takeda for second novel next-generation immuno-oncology bispecific antibody
March 22, 2023Business Services
LONDON, United Kingdom, March, 22, 2023 (GLOBE NEWSWIRE): InvoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited …
Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression
March 22, 2023Business Services
Boston, Massachusetts March 22, 2023 – Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify …
ELLAB LAUNCHES NEW MONITORING SOLUTION FOR LIFE-SAVING PRODUCTS
March 22, 2023Business Services
Ellab has launched a new continuous monitoring solution for the biotech and pharmaceutical sectors, which accurately monitors critical processes 24/7. …
CANARY WHARF ATTRACTS LIFE SCIENCES FOCUSED STARTUPS AND SCALEUPS TO ITS TECHNOLOGY COMMUNITY AT LEVEL39
March 22, 2023Business Services
22 March 2023: The development of a major life science cluster at Canary Wharf continues to build momentum with a …
Sequana Medical announces additional patents for DSR® in China and the United States
March 22, 2023Business Services
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
Roche and Eli Lilly collaborate on Alzheimer’s disease blood test
March 22, 2023Medical Communications
Swiss biotech company Roche has announced a collaboration with US pharmaceutical company Eli Lilly to develop Roche’s Elecsys Amyloid Plasma …
Kite’s Yescarta CAR T-cell therapy shows statistically significant improvement in overall survival
March 22, 2023Research and Development
Kite has announced the primary overall survival (OS) analysis results of a phase 3 study into Yescarta for the treatment …
Promising ovarian cancer drug enters phase 3 trial
March 22, 2023A new drug to treat ovarian cancer is set to enter the phase 3 UP-NEXT trial imminently. Upifitamab rilsodotin is …
Faron Pharmaceuticals announces positive FDA feedback for solid tumour therapy
March 22, 2023Research and Development
Faron Pharmaceuticals, a clinical stage biopharmaceutical company, has revealed positive FDA feedback and recommendations for its monotherapy for solid tumour …
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
March 21, 2023Business Services
OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …
BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody
March 21, 2023Sales and Marketing
BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple …
First candidate from Nurix-Gilead Sciences collaboration exclusively licensed
March 21, 2023Research and Development
US-based Gilead Sciences and Nurix have announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein …
FDA staff appear to support Biogen’s ALS drug despite limited data
March 21, 2023Medical Communications
It appears that the FDA is inclined to support Biogen’s amyotrophic lateral sclerosis (ALS) drug, tofersen, with documents released on …
FDA approves Surgvision’s Explorer Air II device
March 21, 2023Medical Communications
Medical technology company Surgvision has announced that it has received FDA 510(k) approval for its Explorer Air II device. It …
Mobiquity Report Reveals Top Mobile Health App Features that help to increase patient engagement.
March 20, 2023Business Services
Mobiquity, a digital consultancy that designs and delivers innovative digital products and services for the world’s leading brands, released today …
AbbVie shares results from study for new psoriasis therapy
March 20, 2023Research and Development
AbbVie has announced new 52-week data from a study assessing the efficacy of new IL-23 inhibitor, Skyrizi (risankizumab). Patients with …
QurAlis Corporation announces programme which targets UNC13A mis-splicing in neurodegenerative diseases
March 20, 2023Research and Development
US-based clinical-stage biotechnology QurAlis Corporation has announced the launch of its newest programme to treat neurodegenerative diseases like ALS and …
AstraZeneca and MSD announce MHRA marketing authorisation of Lynparza combination therapy
March 20, 2023Medical Communications
AstraZeneca and MSD have announced that the MHRA has granted marketing authorisation for Lynparza (olaparib) in the UK, when used …
Oxford Nanopore and 4bases collaborate on kit for BRCA1 and BRCA2 gene analysis
March 20, 2023Medical Communications
Oxford Nanopore Technologies and Swiss company 4bases have announced a collaboration making 4bases kits with Oxford Nanopore’s sequencing technology. These …
NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)
March 20, 2023Business Services
MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
